Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: Case report

Saul Campos-Gomez*, Humberto Lara-Guerra, Mark J. Routbort, Xinyan Lu, George R. Simon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Chromosomal translocation resulting in the fusion between the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene was recently identified as a novel genetic alteration in a subset of non-small cell lung cancer (NSCLC). EML4-ALK translocations are rare events associated with specific clinicopathological features, such as never or light smoking history, young age and adenocarcinoma with signet ring or acinar histology. Reports suggest ALK gene arrangements are mutually exclusive with EGFR and KRAS mutations. To the best of to our knowledge, this is the first case report of a patient with concurrent KRAS mutation and ALK translocation. This patient had an excellent response to crizotinib, suggesting that the ALK translocation was the oncogenic driver.

Original languageEnglish (US)
Pages (from-to)e254-e257
JournalInternational Journal of Biological Markers
Volume30
Issue number2
DOIs
StatePublished - Jan 1 2015

Keywords

  • EML4-ALK
  • KRAS mutations
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: Case report'. Together they form a unique fingerprint.

Cite this